Compare Pharmarise Holdings Corp. with Similar Stocks
Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 3.11% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Poor long term growth as Net Sales has grown by an annual rate of 3.11% over the last 5 years
3
The company has declared Negative results for the last 5 consecutive quarters
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,259 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
1.44
-0.68%
0.92
Revenue and Profits:
Net Sales:
16,849 Million
(Quarterly Results - Nov 2025)
Net Profit:
128 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.04%
0%
7.04%
6 Months
-12.96%
0%
-12.96%
1 Year
-19.22%
0%
-19.22%
2 Years
-15.52%
0%
-15.52%
3 Years
-28.09%
0%
-28.09%
4 Years
-33.72%
0%
-33.72%
5 Years
-23.41%
0%
-23.41%
Pharmarise Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.11%
EBIT Growth (5y)
-33.14%
EBIT to Interest (avg)
16.35
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
1.73
Sales to Capital Employed (avg)
3.13
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.02%
ROE (avg)
5.48%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.83
EV to EBIT
118.54
EV to EBITDA
11.57
EV to Capital Employed
0.94
EV to Sales
0.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.79%
ROE (Latest)
-2.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ
Nov'25
Aug'25
Change(%)
Net Sales
16,849.00
16,753.00
0.57%
Operating Profit (PBDIT) excl Other Income
636.00
529.00
20.23%
Interest
62.00
61.00
1.64%
Exceptional Items
45.00
1.00
4,400.00%
Consolidate Net Profit
128.00
-22.00
681.82%
Operating Profit Margin (Excl OI)
14.60%
9.10%
0.55%
USD in Million.
Net Sales
QoQ Growth in quarter ended Nov 2025 is 0.57% vs -1.04% in Aug 2025
Consolidated Net Profit
QoQ Growth in quarter ended Nov 2025 is 681.82% vs 77.32% in Aug 2025
Annual Results Snapshot (Consolidated) - May'25
May'25
May'24
Change(%)
Net Sales
63,508.00
54,466.00
16.60%
Operating Profit (PBDIT) excl Other Income
1,788.00
2,086.00
-14.29%
Interest
178.00
66.00
169.70%
Exceptional Items
-129.00
-703.00
81.65%
Consolidate Net Profit
-381.00
-342.00
-11.40%
Operating Profit Margin (Excl OI)
4.60%
16.80%
-1.22%
USD in Million.
Net Sales
YoY Growth in year ended May 2025 is 16.60% vs 4.68% in May 2024
Consolidated Net Profit
YoY Growth in year ended May 2025 is -11.40% vs -198.56% in May 2024
About Pharmarise Holdings Corp. 
Pharmarise Holdings Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






